Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICON-1
- Development stage
- Unknown
- Lead developer
- Iconic Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal, Ophthalmic
01
Overview
ICON-1 is a first-in-class recombinant fusion protein developed by Iconic Therapeutics to target Tissue Factor (TF), a protein overexpressed in various cancers and pathological neovascularization. The molecule is composed of a catalytically inactive human Factor VIIa (FVIIa) domain fused to the Fc region of a human IgG1 antibody. By utilizing the high affinity of FVIIa for TF, ICON-1 acts as an immunoconjugate that binds to TF-expressing tumor cells and pathological blood vessels. The IgG1 Fc domain then recruits immune effector cells, such as natural killer (NK) cells, to induce antibody-dependent cell-mediated cytotoxicity (ADCC), leading to the destruction of the target cells. In uveal melanoma, ICON-1 has been investigated via intravitreal injection to evaluate its safety and ability to target ocular tumor cells in patients scheduled for surgical interventions.
- Other names
- FVIIa-Fc fusion proteinFactor VIIa-Fc fusion protein
02
Targets
F3 (Tissue factor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on ICON-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICON-1.